Sibaud Vincent, Garrido-Stowhas Ignacio, Cottura Ewa, Chevreau Christine
Institut Claudius-Regaud, Toulouse cedex, France.
Bull Cancer. 2011 Oct;98(10):1221-9. doi: 10.1684/bdc.2011.1457.
While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events. The signaling pathways and/or receptors inhibited by these new drugs are often physiologically expressed in the skin and/or hair follicle and cutaneous toxicity is on the forefront. This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab.
虽然新型抗癌血管生成抑制剂具有耐受性良好的安全性，但并非没有不良事件。这些新药所抑制的信号通路和/或受体通常在皮肤和/或毛囊中生理表达，皮肤毒性最为突出。本文综述了这些具有部分或完全抗血管生成活性的靶向抗癌治疗药物（索拉非尼、舒尼替尼、帕唑帕尼、凡德他尼、依维莫司、替西罗莫司或贝伐单抗）引起的主要皮肤不良事件。
